ESMFold2, released by Chan Zuckerberg Biohub in May 2026, is a state-of-the-art bioinformatics model that accurately predicts the 3D conformation of a protein using only single amino acid sequence information, without the need to generate large-scale multiple sequence alignments. Previous generations of protein folding models required significant time, often tens of minutes, to query and align homologous sequences from massive, gigabyte-sized databases to calculate the evolutionary relationships and distance constraints between amino acids. In contrast, this model bypasses the complex pre-processing query process entirely and restores accurate 3D structures within seconds by leveraging ESMC, a 6B parameter protein language model that deeply learns the evolutionary context and structural patterns inherent in protein amino acid sequence information. This is similar to how a large language model like GPT learns from billions of sentence data to generate the most contextually natural flow of words; ESMFold2 recognizes the flow of residue arrangements within a protein domain and infers the structural plausibility of a protein's 3D morphology that can exist in nature in real-time. Previously widely used methods, such as AlphaFold, required significant time and the use of dozens of high-performance computer nodes and vast database disks to analyze a single protein structure, which posed a serious limitation in terms of speed for real-time protein design research or large-scale genomic analysis involving the screening of tens of thousands of variants. ESMFold2 dramatically reduces processing speed by not relying on these high-cost sequence alignment pipelines and instead using single-sequence folding, ensuring overwhelming efficiency by allowing the conversion of tens of sequences into structural space per second. Furthermore, by incorporating a sophisticated diffusion model decoder as the structure generation component, it overcomes the limitations of conventional single-sequence models in predicting multi-domain structures and maintains a high level of prediction accuracy even for complex structures such as protein complexes or viral capsids. Thanks to these computational innovations, modern biotechnology researchers can now design and experimentally validate novel bio-binders or single-chain variable region (scFv) fragments optimized for disease target proteins, such as EGFR, a target for cancer therapy, or PD-L1, a key component of immune checkpoint inhibitors, in just a few days. In addition, it can rapidly decode the folding patterns of previously unknown proteins from environmental sources belonging to unknown evolutionary lineages, which was virtually impossible with conventional methods, accelerating the development of novel enzymes and the discovery of biological resources for climate change mitigation by a factor of hundreds. In short, ESMFold2 is more than just a tool for generating 3D coordinates of proteins; it is becoming a powerful microscope that rapidly projects the entire genomic sequencing data into the world of 3D structures and a key indicator for molecular engineering.

Released in May 2026 by the Chan Zuckerberg Biohub, ESMFold2 is a state-of-the-art bioinformatics model that accurately predicts the 3D spatial structure of a protein using only single amino acid sequence information, without the need to generate a large number of multiple sequence alignments. Previous generations of protein folding models required tens of minutes to search and align homologous sequences from gigabyte-sized databases in order to calculate the evolutionary relationships and distance constraints between amino acids.

De Novo Minibinder Design: Rapidly model the 3D interaction structure of ultra-small binding proteins that specifically bind to a target protein (e.g., EGFR, PD-L1) and perform binding affinity optimization simulations.